MERCK & CO. INC. (6MK.DE) Stock Fundamental Analysis

FRA:6MK • US58933Y1055

104 EUR
+2.4 (+2.36%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to 6MK. 6MK was compared to 49 industry peers in the Pharmaceuticals industry. While 6MK has a great profitability rating, there are some minor concerns on its financial health. 6MK has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • 6MK had positive earnings in the past year.
  • In the past year 6MK had a positive cash flow from operations.
  • In the past 5 years 6MK has always been profitable.
  • 6MK had a positive operating cash flow in 4 of the past 5 years.
6MK.DE Yearly Net Income VS EBIT VS OCF VS FCF6MK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

1.2 Ratios

  • With an excellent Return On Assets value of 14.69%, 6MK belongs to the best of the industry, outperforming 88.46% of the companies in the same industry.
  • The Return On Equity of 6MK (36.71%) is better than 86.54% of its industry peers.
  • With an excellent Return On Invested Capital value of 20.32%, 6MK belongs to the best of the industry, outperforming 82.69% of the companies in the same industry.
Industry RankSector Rank
ROA 14.69%
ROE 36.71%
ROIC 20.32%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
6MK.DE Yearly ROA, ROE, ROIC6MK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • 6MK has a Profit Margin of 29.63%. This is amongst the best in the industry. 6MK outperforms 92.31% of its industry peers.
  • In the last couple of years the Profit Margin of 6MK has grown nicely.
  • With an excellent Operating Margin value of 36.99%, 6MK belongs to the best of the industry, outperforming 90.38% of the companies in the same industry.
  • In the last couple of years the Operating Margin of 6MK has grown nicely.
  • 6MK has a better Gross Margin (77.69%) than 80.77% of its industry peers.
  • In the last couple of years the Gross Margin of 6MK has grown nicely.
Industry RankSector Rank
OM 36.99%
PM (TTM) 29.63%
GM 77.69%
OM growth 3Y6.33%
OM growth 5Y9.38%
PM growth 3Y4.66%
PM growth 5Y10.53%
GM growth 3Y4.72%
GM growth 5Y2.48%
6MK.DE Yearly Profit, Operating, Gross Margins6MK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 6MK is creating value.
  • There is no outstanding debt for 6MK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
6MK.DE Yearly Shares Outstanding6MK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
6MK.DE Yearly Total Debt VS Total Assets6MK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 4.41 indicates that 6MK is not in any danger for bankruptcy at the moment.
  • 6MK has a Altman-Z score of 4.41. This is in the better half of the industry: 6MK outperforms 61.54% of its industry peers.
  • 6MK has a debt to FCF ratio of 3.17. This is a good value and a sign of high solvency as 6MK would need 3.17 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 3.17, 6MK is doing good in the industry, outperforming 73.08% of the companies in the same industry.
  • 6MK has a Debt/Equity ratio of 0.77. This is a neutral value indicating 6MK is somewhat dependend on debt financing.
  • 6MK has a Debt to Equity ratio of 0.77. This is comparable to the rest of the industry: 6MK outperforms 44.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 3.17
Altman-Z 4.41
ROIC/WACC2.28
WACC8.9%
6MK.DE Yearly LT Debt VS Equity VS FCF6MK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

  • A Current Ratio of 1.66 indicates that 6MK should not have too much problems paying its short term obligations.
  • The Current ratio of 6MK (1.66) is better than 67.31% of its industry peers.
  • 6MK has a Quick Ratio of 1.44. This is a normal value and indicates that 6MK is financially healthy and should not expect problems in meeting its short term obligations.
  • 6MK has a better Quick ratio (1.44) than 76.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.44
6MK.DE Yearly Current Assets VS Current Liabilites6MK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.16% over the past year.
  • 6MK shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.13% yearly.
  • Looking at the last year, 6MK shows a small growth in Revenue. The Revenue has grown by 1.31% in the last year.
  • 6MK shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.38% yearly.
EPS 1Y (TTM)20.16%
EPS 3Y7.06%
EPS 5Y9.13%
EPS Q2Q%21.51%
Revenue 1Y (TTM)1.31%
Revenue growth 3Y3.12%
Revenue growth 5Y9.38%
Sales Q2Q%4.97%

3.2 Future

  • Based on estimates for the next years, 6MK will show a small growth in Earnings Per Share. The EPS will grow by 1.63% on average per year.
  • Based on estimates for the next years, 6MK will show a small growth in Revenue. The Revenue will grow by 2.49% on average per year.
EPS Next Y-41.06%
EPS Next 2Y4.38%
EPS Next 3Y5.65%
EPS Next 5Y1.63%
Revenue Next Year2.98%
Revenue Next 2Y4.12%
Revenue Next 3Y4.9%
Revenue Next 5Y2.49%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
6MK.DE Yearly Revenue VS Estimates6MK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B
6MK.DE Yearly EPS VS Estimates6MK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 13.37, the valuation of 6MK can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of 6MK indicates a somewhat cheap valuation: 6MK is cheaper than 75.00% of the companies listed in the same industry.
  • 6MK is valuated cheaply when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
  • 6MK is valuated rather expensively with a Price/Forward Earnings ratio of 22.69.
  • 6MK's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. 6MK is around the same levels.
Industry RankSector Rank
PE 13.37
Fwd PE 22.69
6MK.DE Price Earnings VS Forward Price Earnings6MK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, 6MK is valued a bit cheaper than the industry average as 67.31% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, 6MK is valued a bit cheaper than 63.46% of the companies in the same industry.
Industry RankSector Rank
P/FCF 23.35
EV/EBITDA 11.57
6MK.DE Per share data6MK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • 6MK has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.46
EPS Next 2Y4.38%
EPS Next 3Y5.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • 6MK has a Yearly Dividend Yield of 2.85%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 1.84, 6MK pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, 6MK pays a better dividend.
Industry RankSector Rank
Dividend Yield 2.85%

5.2 History

  • The dividend of 6MK has a limited annual growth rate of 5.92%.
Dividend Growth(5Y)5.92%
Div Incr Years8
Div Non Decr Years8
6MK.DE Yearly Dividends per share6MK.DE Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3

5.3 Sustainability

  • 6MK pays out 42.60% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • 6MK's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP42.6%
EPS Next 2Y4.38%
EPS Next 3Y5.65%
6MK.DE Yearly Income VS Free CF VS Dividend6MK.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B
6MK.DE Dividend Payout.6MK.DE Dividend Payout, showing the Payout Ratio.6MK.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MERCK & CO. INC.

FRA:6MK (2/27/2026, 7:00:00 PM)

104

+2.4 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-03
Earnings (Next)04-30
Inst Owners80.32%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap258.13B
Revenue(TTM)65.01B
Net Income(TTM)19.03B
Analysts77.06
Price Target108.2 (4.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.85%
Yearly Dividend2.77
Dividend Growth(5Y)5.92%
DP42.6%
Div Incr Years8
Div Non Decr Years8
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.37%
Min EPS beat(2)7.69%
Max EPS beat(2)13.06%
EPS beat(4)4
Avg EPS beat(4)7.28%
Min EPS beat(4)2.93%
Max EPS beat(4)13.06%
EPS beat(8)8
Avg EPS beat(8)21.72%
EPS beat(12)12
Avg EPS beat(12)16.45%
EPS beat(16)16
Avg EPS beat(16)15.36%
Revenue beat(2)1
Avg Revenue beat(2)-0.35%
Min Revenue beat(2)-1.54%
Max Revenue beat(2)0.83%
Revenue beat(4)2
Avg Revenue beat(4)-0.09%
Min Revenue beat(4)-1.54%
Max Revenue beat(4)0.83%
Revenue beat(8)5
Avg Revenue beat(8)0.41%
Revenue beat(12)9
Avg Revenue beat(12)1.14%
Revenue beat(16)13
Avg Revenue beat(16)1.98%
PT rev (1m)10.57%
PT rev (3m)21.01%
EPS NQ rev (1m)0.09%
EPS NQ rev (3m)-2.25%
EPS NY rev (1m)-5.38%
EPS NY rev (3m)-43.18%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)-1.42%
Revenue NY rev (3m)-1.86%
Valuation
Industry RankSector Rank
PE 13.37
Fwd PE 22.69
P/S 4.74
P/FCF 23.35
P/OCF 17.86
P/B 5.88
P/tB 20.38
EV/EBITDA 11.57
EPS(TTM)7.78
EY7.48%
EPS(NY)4.58
Fwd EY4.41%
FCF(TTM)4.45
FCFY4.28%
OCF(TTM)5.82
OCFY5.6%
SpS21.92
BVpS17.7
TBVpS5.1
PEG (NY)N/A
PEG (5Y)1.46
Graham Number55.66
Profitability
Industry RankSector Rank
ROA 14.69%
ROE 36.71%
ROCE 23.54%
ROIC 20.32%
ROICexc 24.8%
ROICexgc 44.78%
OM 36.99%
PM (TTM) 29.63%
GM 77.69%
FCFM 20.31%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y6.33%
OM growth 5Y9.38%
PM growth 3Y4.66%
PM growth 5Y10.53%
GM growth 3Y4.72%
GM growth 5Y2.48%
F-Score6
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 3.17
Debt/EBITDA 1.41
Cap/Depr 87.9%
Cap/Sales 6.25%
Interest Coverage 17.91
Cash Conversion 60.24%
Profit Quality 68.56%
Current Ratio 1.66
Quick Ratio 1.44
Altman-Z 4.41
F-Score6
WACC8.9%
ROIC/WACC2.28
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.16%
EPS 3Y7.06%
EPS 5Y9.13%
EPS Q2Q%21.51%
EPS Next Y-41.06%
EPS Next 2Y4.38%
EPS Next 3Y5.65%
EPS Next 5Y1.63%
Revenue 1Y (TTM)1.31%
Revenue growth 3Y3.12%
Revenue growth 5Y9.38%
Sales Q2Q%4.97%
Revenue Next Year2.98%
Revenue Next 2Y4.12%
Revenue Next 3Y4.9%
Revenue Next 5Y2.49%
EBIT growth 1Y-0.15%
EBIT growth 3Y9.65%
EBIT growth 5Y19.64%
EBIT Next Year-19.93%
EBIT Next 3Y10.24%
EBIT Next 5Y2.8%
FCF growth 1Y-12.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.56%
OCF growth 3YN/A
OCF growth 5YN/A

MERCK & CO. INC. / 6MK.DE FAQ

Can you provide the ChartMill fundamental rating for MERCK & CO. INC.?

ChartMill assigns a fundamental rating of 6 / 10 to 6MK.DE.


What is the valuation status for 6MK stock?

ChartMill assigns a valuation rating of 5 / 10 to MERCK & CO. INC. (6MK.DE). This can be considered as Fairly Valued.


What is the profitability of 6MK stock?

MERCK & CO. INC. (6MK.DE) has a profitability rating of 8 / 10.


What are the PE and PB ratios of MERCK & CO. INC. (6MK.DE) stock?

The Price/Earnings (PE) ratio for MERCK & CO. INC. (6MK.DE) is 13.37 and the Price/Book (PB) ratio is 5.88.


Is the dividend of MERCK & CO. INC. sustainable?

The dividend rating of MERCK & CO. INC. (6MK.DE) is 5 / 10 and the dividend payout ratio is 42.6%.